|
| |
Ligand PharmaceuticalsLigand is an emerging specialty pharmaceutical company that discovers, develops and markets innovative small molecule drugs to address critical, unmet medical needs. Ligand markets four oncology and dermatology products in the United States – ONTAK®, Targretin® capsules, Targretin® gel and Panretin® gel. Ligand launched its fifth product, AVINZA™, a treatment for chronic, moderate-to-severe pain, in the second quarter of this year. In addition, Ligand's network of major pharmaceutical partners is developing products for men's and women's hormone-related diseases, osteoporosis, metabolic disorders, and cardiovascular and inflammatory diseases. Ligand's robust R&D pipeline is based on the company's leadership in gene transcription technology.
| Contact Details: |
| 10275 Science Center Drive |
| San Diego |
| CA |
| 92121-1117 |
| United States of America |
| Tel: | 858 550 7500 |
| Fax: | 858 550 7506 |
| Email: | investors@ligand.com |
| WWW: | www.ligand.com/
|
|
Loading...
|
Recent Publications by Ligand Pharmaceuticals: |  |
2-Benzimidazolyl-9-(chroman-4-yl)-purinone derivatives as JAK3 inhibitors.
A novel class of Janus tyrosine kinase 3 (JAK3) inhibitors based on a... | 20th October, 2009
| Ligand Pharmaceuticals,
| Bioorg Med Chem Lett. 2009 Dec 1;19(23):6788-92. Epub 2009 Sep 25.
DOI Direct Link |
Triazine and pyrimidine based ROCK inhibitors with efficacy in spontaneous hypertensive rat model.
The profile of a series of triazine and pyrimidine based ROCK inhibitors... | 6th October, 2009
| Ligand Pharmaceuticals, Inc., 3000 Eastpark Boulevard, Cranbury, NJ 08512,
| Bioorg Med Chem Lett. 2009 Nov 1;19(21):6027-31. Epub 2009 Sep 17.
DOI Direct Link |
Combination treatment with a selective androgen receptor modulator q(SARM) and a bisphosphonate has additive effects in osteopenic female rats.
Recent clinical trials with bisphosphonates and PTH have not supported the... | 29th August, 2009
| Discovery Research, Ligand Pharmaceuticals, San Diego, California 92121,
| J Bone Miner Res. 2009 Feb;24(2):231-40.
DOI Direct Link |
Novel CXCR3 antagonists with a piperazinyl-piperidine core.
High-throughput screening of an encoded combinatorial aryl piperazine... | 4th August, 2009
| Ligand Pharmaceuticals, 3000 Eastpark Boulevard, Cranbury, NJ 08512, USA.
| Bioorg Med Chem Lett. 2009 Sep 1;19(17):5205-8. Epub 2009 Jul 9.
DOI Direct Link |
Pharmacokinetics and pharmacodynamics of LGD-3303 [9-chloro-2-ethyl-1-methyl-3-(2,2,2-trifluoroethyl)-3H-pyrrolo-[3,2-f]quin olin-7(6H)-one], an orally available nonsteroidal-selective androgen receptor modulator.
Selective androgen receptor modulators (SARMs) are a new class of... | 24th February, 2009
| Discovery Research, Ligand Pharmaceuticals, Inc., San Diego, California,
| J Pharmacol Exp Ther. 2009 Feb;328(2):663-70. Epub 2008 Nov 18.
DOI Direct Link |
→View more Ligand Pharmaceuticals research publications. |
Press Releases on Ligand Pharmaceuticals:
|
 |
| Sequenom Reports Third Quarter 2009 Financial Results |
9th November, 2009 |
Sequenom, Inc. |
-- Net loss for the third quarter of 2009 was $14.9 million, or $0.24 per
share, compared with $10.4 million, or $0.18 per share, for the third
quarter of 2008.
Nine-Month
|
| Sequenom Announces Paul Maier to Become Interim Chief Financial Officer |
26th October, 2009 |
Sequenom, Inc. |
SAN DIEGO, Oct. 26 /PRNewswire-FirstCall/ -- Sequenom, Inc. (Nasdaq: SQNM), today announced that Paul V. Maier has been appointed as the company's interim chief financial officer effective
|
| Techne Corporation Announces That John L. Higgins has Accepted a Seat on Techne's Board |
19th May, 2009 |
Techne Corporation |
MINNEAPOLIS, May 19 /PRNewswire-FirstCall/ -- Techne Corporation (Nasdaq: TECH) today announced that Mr. John L. Higgins has accepted a position on Techne's Board of Directors and will also serve
|
| GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP |
6th December, 2008 |
GlaxoSmithKline |
PHILADELPHIA, Dec. 6 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK)
announced positive safety and efficacy results from RAISE (RAndomized placebo-
controlled ITP Study with Eltrombopag), a
|
BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 42 individuals from Ligand Pharmaceuticals using this service.  Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 1307 times since April 2007, the link to the organisation's website has been followed 203 times Recent Search Terms used to find this page: ligand pharmaceuticals patents | ligand pharmaceuticals opinion | ligand pharmaceuticals uk | Ligand Pharmaceuticals UK Ltd | Ligand Pharmaceuticals in uk | Ligand Pharmaceuticals in uk | mark anderson ligand | Ligand Pharmaceuticals in uk | Ligand Pharmaceuticals in uk | Ligand Pharmaceuticals in uk | . Search for more companies in San Diego Search for more companies in CA This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Ligand Pharmaceuticals |
